Table 5.

Effect of Treatment on Risk of Loss of Visual Acuity Score of ≥15 Letters From Baseline^*

	Participants in AMD Categories 2, 3, and 4 (n = 3597)		Participants in AMD Categories 3 and 4 (n = 2549)
Treatment	OR (99% CI)	PValue	OR (99% CI)	PValue
Antioxidants vs no antioxidants	0.90 (0.74–1.09)	.14	0.86 (0.70–1.07)	.07
Zinc vs no zinc	0.88 (0.73–1.07)	.09	0.84 (0.68–1.04)	.04
Antioxidants vs placebo	0.88 (0.67–1.15)	.22	0.85 (0.63–1.14)	.16
Adjusted	0.87 (0.67–1.15)	.20†	0.87 (0.65–1.17)	.23†
Zinc vs placebo	0.87 (0.66–1.13)	.17	0.83 (0.62–1.11)	.10
Adjusted	0.82 (0.63–1.08)	.07†	0.82 (0.61–1.09)	.07†
Antioxidants + zinc vs placebo	0.79 (0.60–1.04)	.03	0.73 (0.54–0.99)	.008
Adjusted	0.77 (0.58–1.03)	.02†	0.75 (0.55–1.02)	.017†
Total No. of participants with events	1197		1022

^*AMD indicates age-related macular degeneration; OR, odds ratio; and CI, confidence interval. Analysis by repeated-measures logistic regression, unadjusted. P≤.01 is considered statistically significant.

^†Adjusted for age, sex, race, AMD category, and baseline smoking status.